Stocks to sell

While Senseonics (NYSE:SENS) stock has a great deal of potential, the shares currently have a fairly high valuation. Source: Minerva Studio / Shutterstock.com Moreover, in the short-term and medium-term, SENS stock looks poised to fall significantly. Senseonics has developed Eversense, a 90-day continuous glucose monitoring (CGM) system. According to the company, the device provides continuous
0 Comments
With Zomedica’s  (NYSE:ZOM) new Truforma diagnostic tool possibly facing a great deal of entrenched competition, the outlook of ZOM stock is, at best, difficult to determine. Meanwhile, the shares have a very high valuation. Source: didesign021 / Shutterstock.com A diagnostic product meant to be used by veterinarians, Truforma measures the amount of T4 and TSH
0 Comments
Lordstown Motors (NASDAQ:RIDE) stock, the electric car start-up, took a hard fall but then rose again on a management re-shuffle. Source: Postmodern Studio / Shutterstock.com The company admitted misstatements in demand for its Endurance pick-up. Then it accepted the resignations of CEO Steve Burns and CFO Julio Rodriguez. Becky Roof, an accountant who has been
0 Comments
For some strange reason, Reddit’s WallStreetBets embraced the short-squeeze of AMC Entertainment Holdings (NYSE:AMC). While its business is on the cusp of recovering, its earnings will not get anywhere near a level that justifies its valuation. Its market capitalization, which exceeded that of GameStop (NYSE:GME) at the end of last week, is most puzzling. For
0 Comments
InvestorPlace columnist Brenden Rearick recently discussed Castor Maritime’s (NASDAQ:CTRM) first profitable quarter since 2019. Interestingly, despite the positive results, CTRM stock fell on the news.  Source: Pavel Kapysh / Shutterstock.com Rearick points out that the company is ready to take advantage of the “strong demand for dry bulk transportation services” with 18 dry bulk carriers
0 Comments
Biogen (NASDAQ:BIIB) stock ripped higher this week on approval of its Alzheimer’s drug, Aduhelm. Source: PictureDesignSwiss / Shutterstock.com Analysts seemed taken with Biogen’s proposed pricing, $56,000 per year. It’s based on the cost of Alzheimer’s in lost life and nursing care. A scientific panel refused to endorse the drug last year. The panel voted 8-1
0 Comments